Medtronic has agreed to acquire Scientia Vascular, a Salt Lake City-based developer of neurovascular access devices, in a deal valued at $550 million, according to an announcement from the Galway, Ireland-based medical technology company.

The transaction, which remains subject to regulatory approvals and customary closing conditions, is expected to close in the first half of Medtronic’s fiscal year 2027. The company said the acquisition could include additional earn-out and milestone payments. Medtronic expects the deal to be minimally dilutive to adjusted earnings per share in fiscal 2027 and accretive thereafter.

Scientia Vascular, founded by chief technology officer John Lippert, employs about 310 people and focuses on guidewires and catheter technologies used in neurovascular procedures. These devices are designed to help physicians navigate complex cerebral anatomy when treating conditions such as ischemic stroke or aneurysms.
Medtronic said the company’s access devices will complement its existing neurovascular portfolio, which includes stent retrievers, flow diverters and liquid embolic systems used in stroke and hemorrhagic interventions. By integrating access technologies with therapeutic devices, the company aims to support physicians throughout the full procedural workflow.

“Medtronic is thrilled to acquire Scientia to accelerate meaningful innovation in neurovascular care,” said Linnea Burman, senior vice president and president of Medtronic’s neurovascular business. “This acquisition positions Medtronic with a full suite of products. It builds a strong foundation for Medtronic and supports procedures across both hemorrhagic and acute ischemic stroke.”

Stroke remains a major global health burden. Medtronic noted that about 12 million people worldwide experience stroke each year, and delays in restoring blood flow can result in rapid loss of brain tissue.

Devices such as microcatheters and microwires are widely used in neurointerventional procedures to access blocked or damaged blood vessels. Dr. David Fiorella, director of the cerebrovascular center at Stony Brook Medicine, said improvements in these tools can influence procedural efficiency and safety.

“Microwires and microcatheters are required for all neurointerventional cases,” Fiorella said. “Correspondingly, better microwires and microcatheters make every single case technically easier, faster, and ultimately safer for patients.”

Scientia CEO Rick Randall said the acquisition will allow the company’s technologies to reach a broader global market through Medtronic’s scale and distribution network.

Stroke Homepage